| Preferred Home Care Services | |
| 2802 Madison Square Drive Ste 100, Loveland, Colorado 80538 | |
| (970) 776-1970 | |
| Name | Preferred Home Care Services |
|---|---|
| Location | 2802 Madison Square Drive Ste 100, Loveland, Colorado |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 67215 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 80513, 80521, 80524, 80525, 80526, 80528, 80534, 80535, 80537, 80538, 80543, 80547, 80549, 80550, 80610, 80615, 80620, 80631, 80634, 80650 |
| NPI Number | 1548389836 |
| Organization Name | PREFERRED MOBILE NURSES, INC. |
| Doing Business As | PREFERRED HOME HEALTH; PREFERRED HOME CARE SERVICES |
| Address | 2802 Madison Square Drive, Suite 100, Loveland, CO 80538 |
| Phone Number | 970-776-1970 |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
| Quality Rating: |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 91.9 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 87.1 | 98.6 |
| How often the home health team checked patients’ risk of falling | 97.9 | 99.6 |
| How often the home health team checked patients for depression | 91.1 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 90.7 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 86.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 67.7 | 96.4 |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 66.4 | 79.6 |
| How often patients got better at getting in and out of bed | 81.4 | 81.1 |
| How often patients got better at bathing | 79.6 | 82.3 |
| How often patients’ breathing improved | 82.5 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 65.8 | 75 |
| How often home health patients had to be admitted to the hospital | 14.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 18 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 76.7 | 94 |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
The patient survey data of Preferred Home Care Services is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 83 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 92 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 85 | 78 |
News Archive
Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.
A team of researchers from Rice University has won a National Science Foundation (NSF) RAPID grant to adapt their wastewater nanotechnology project to help trap and inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (which causes COVID-19 disease), in wastewater. This could help public health officials deal with the threat of disease transmission through wastewater.
OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.
Researchers at Lund University in Sweden, in collaboration with colleagues in Dresden, Germany, have developed a way of combining a bone substitute and drugs to regenerate bone and heal severe fractures in the thigh or shin bone.
› Verified 7 days ago
Banner Home Care Colorado Location: 1810 N Boise, Loveland, Colorado 80538 Ratings: Phone: (970) 820-4435 | |
Canyon Home Care And Hospice Of Loveland Location: 350 E 7th Street Suite 2, Loveland, Colorado 80537 Ratings: Phone: (970) 330-5655 | |
Good Samaritan Society-colorado Home Care Location: 2101 South Garfield Ave, Loveland, Colorado 80537 Ratings: Phone: (970) 635-2970 | |
Preferred Home Care Services Location: 2802 Madison Square Drive Ste 100, Loveland, Colorado 80538 Ratings: Phone: (970) 776-1970 | |
Tender Care Pediatric Services Inc Location: 5677 Boeing Drive, Loveland, Colorado 80538 Ratings: NA Phone: (970) 686-5437 | |
Encompass Health Home Health Location: 2171 Citrine Court, Loveland, Colorado 80537 Ratings: Phone: (970) 493-8500 |